Received 13 January 2004.
Mutational analysis of the ARAF gene in human cancers†
Version of Record online: 27 JAN 2005
Volume 113, Issue 1, pages 54–7, January 2005
How to Cite
LEE, J. W., SOUNG, Y. H., KIM, S. Y., PARK, W. S., NAM, S. W., MIN, W. S., KIM, S. H., LEE, J. Y., YOO, N. J. and LEE, S. H. (2005), Mutational analysis of the ARAF gene in human cancers. APMIS, 113: 54–7. doi: 10.1111/j.1600-0463.2005.apm1130108.x
Accepted 9 September 2004.
- Issue online: 27 JAN 2005
- Version of Record online: 27 JAN 2005
Deregulation of RAS signal transduction has been implicated in the malignant growth of human cancer cells. The BRAF gene, encoding a RAF family member in the downstream pathway of RAS, is somatically mutated in a number of human cancers, raising the possibility that other RAF family members might be mutated in human cancers. In this study we analyzed the genomic DNAs for the detection of somatic mutations of the ARAF gene in 60 human cancer cell lines and 323 primary human cancer tissues, including colorectal carcinomas, gastric carcinomas, ovarian tumors and acute leukemias. The MOLT-4 leukemia cell line was found to harbor an ARAF gene mutation resulting in an amino acid substitution (A451T) at the activation segment in the kinase domain of ARAF. In the cancer tissues we could not detect any ARAF gene mutation. Our data indicate that, in contrast to the BRAF gene, the ARAF gene is rarely mutated in human cancers, and suggest that alterations of the RAS pathway by ARAF gene mutation may not play an important role in the pathogenesis of human cancers.